Schoenen J, Sawyer J
University Department of Neurology, CHR Citadelle, Liege, Belgium.
Cephalalgia. 1997 Oct;17 Suppl 18:28-40. doi: 10.1177/0333102497017S1805.
The efficacy of zolmitriptan (Zomig, 311C90), a 5-hydroxytryptamine (5HT)1B/1D receptor agonist, in the acute oral treatment of migraine was evaluated in an extensive clinical trial program. Four randomized, placebo-controlled studies (total 2480 patients) were performed; data from two of these trials established that a 2.5 mg dose was on the shoulder of the dose-response curve (2-h headache response rate 64%), showing similar efficacy to the 5 mg dose (67%). In this program, the efficacy of zolmitriptan was not influenced by the pretreatment headache duration; the presence of aura preceding the headache, migraine associated with menses or migraine upon awakening; or by concomitant use of oral contraceptives or antidepressants. In addition, zolmitriptan 5 mg proved consistently effective in the treatment of multiple migraine attacks for up to 1 year. Zolmitriptan reduced the incidence of nausea, photophobia and phonophobia, reduced impairment of normal activity and demonstrated positive effects on patients' quality of life. Thus, zolmitriptan is a highly effective acute oral antimigraine therapy, with 2.5 mg providing the optimal balance between efficacy and tolerability.
在一项广泛的临床试验项目中，对5-羟色胺（5HT）1B/1D受体激动剂佐米曲普坦（佐米格，311C90）在偏头痛急性口服治疗中的疗效进行了评估。开展了四项随机、安慰剂对照研究（共2480例患者）；其中两项试验的数据表明，2.5毫克剂量处于剂量反应曲线的上升阶段（2小时头痛缓解率为64%），显示出与5毫克剂量（67%）相似的疗效。在该项目中，佐米曲普坦的疗效不受治疗前头痛持续时间、头痛前是否有先兆、与月经相关的偏头痛或晨起偏头痛的影响；也不受同时使用口服避孕药或抗抑郁药的影响。此外，5毫克佐米曲普坦在长达1年的多次偏头痛发作治疗中持续有效。佐米曲普坦降低了恶心、畏光和畏声的发生率，减少了对正常活动的损害，并对患者的生活质量产生了积极影响。因此，佐米曲普坦是一种高效的偏头痛急性口服治疗药物，2.5毫克剂量在疗效和耐受性之间提供了最佳平衡。
